STAT+

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-04T14:50:14.295Z • Permanent link

FDA Commissioner Robert M. Califf's office announced a comprehensive review of botanical drugs, prompting widespread interest among researchers, regulators, and industry stakeholders. This development is a significant departure from the agency's previous stance, which has generally been cautious when it comes to approving plant-based treatments. The FDA's decision to revisit botanical drugs could pave the way for a new wave of plant-derived medicines, potentially altering the landscape of the biotech industry.

Critics argue that the FDA's previous approach has stifled innovation, particularly in countries like China and India where traditional medicine plays a significant role in public health. In 2018, the FDA established a framework for evaluating botanical drugs, but many industry experts felt that the guidelines were too restrictive. Now, with the FDA taking a fresh look, researchers are eager to explore the potential of botanicals to tackle pressing health issues.

Regulatory experts point to the FDA's decision as a significant shift in the agency's approach to botanical drugs. Dr. Jeffrey S. Shuren, the FDA's Commissioner for Foods and Drugs, has been a vocal advocate for greater flexibility in evaluating plant-based treatments. The agency's review of botanical drugs is expected to involve a thorough examination of the safety, efficacy, and quality of these products.

The FDA's decision to review botanical drugs has significant implications for companies like Bayer, Merck, and Johnson & Johnson, which are already investing heavily in plant-based research. For instance, Bayer's portfolio includes a range of botanical-derived treatments, including its popular botanical-based pain relief medication, Bengay. Merck, meanwhile, has been exploring the use of botanicals to develop new treatments for conditions like cancer and Alzheimer's disease.

The FDA's review of botanical drugs also has broader implications for the biotech industry as a whole. As the global demand for plant-based treatments continues to grow, companies are increasingly looking to the FDA for guidance on how to navigate the regulatory landscape. The agency's decision to take a more nuanced approach to botanicals could pave the way for new partnerships between industry and academia, driving innovation and advancing our understanding of the complex relationships between plants and human health.

The FDA's review of botanical drugs is part of a larger trend in regulatory agencies around the world to reexamine their approaches to plant-based treatments. In 2020, the European Medicines Agency (EMA) established a new regulatory framework for botanicals, which has encouraged industry stakeholders to invest in plant-based research. Meanwhile, the Chinese government has launched a series of initiatives aimed at promoting the development of plant-based treatments, including a 2022 policy aimed at supporting the growth of the domestic botanical industry.